The verdict
Our read at a glance.
Whether raising a man's own testosterone without shutting down his fertility is established well enough to prescribe, given the drug was never approved for it.
- The signal
- The randomized evidence is better than most things on this Watchlist. Trials showed oral enclomiphene raised endogenous testosterone while maintaining sperm concentration, including in obese men with secondary hypogonadism, and direct comparisons against topical testosterone showed the expected divergence: both raised testosterone, only enclomiphene left spermatogenesis intact. Systematic reviews in 2023 and 2025 comparing clomiphene and enclomiphene for male hypogonadism reach broadly consistent conclusions, and a 2026 British Society of Sexual Medicine position statement addresses its potential use directly. This is a real evidence base, not a rumour.
- The unknown
- Why the NDA failed and what that implies. FDA issued a complete response letter and the drug was never approved; development was subsequently discontinued. There is no long-term outcome data on cardiovascular risk, bone, or prostate under years of use, and no approved-product manufacturing standard behind what patients actually receive.
- Our read
- The inverse of the usual gray-market story. The evidence is real and randomized; the regulatory status is the problem. A drug that works in trials and was still not approved is a drug where something in the risk-benefit or the filing did not satisfy the regulator, and prescribing it compounded does not resolve whatever that was. Judge it on that gap, not on the trial abstracts alone.
The mechanism
How it works.
Clomiphene is a mixture of two isomers with opposite tendencies. Enclomiphene is the trans isomer, and it acts as an oestrogen receptor antagonist in the hypothalamus and pituitary. The brain monitors oestrogen as its readout of how much testosterone is around, because testosterone is converted to oestradiol. Block that receptor and the brain concludes there is not enough, so it raises gonadotropin-releasing hormone, and the pituitary raises luteinising hormone and follicle stimulating hormone. LH tells the testes to make more testosterone; FSH supports sperm production. That is the whole point of the design: because the stimulus travels through the man's own axis rather than replacing the hormone from outside, the testes keep working, and spermatogenesis is preserved instead of being switched off.
Safety & regulatory boundary
The consequential part.
Not approved by FDA or EMA for any indication. Every prescription in the United States is for a compounded preparation, which means product identity, potency and purity depend on the compounding pharmacy rather than on an approved manufacturing standard. Exposure has been associated with interfrontal defects in a published safety analysis, and the class carries the ocular and mood effects known from clomiphene. Prohibited in sport as a hormone and metabolic modulator.
What's next
What we're watching.
Any new sponsor taking it back through an NDA, FDA action on compounded enclomiphene, and long-term safety data from the large prescribing base that now exists outside trials.
Context
Why this is discussed.
Standard testosterone replacement suppresses sperm production. Enclomiphene is the best-known answer to that problem, and telehealth clinics sell it heavily to men who want the testosterone without the infertility.
The evidence base
11 cited references.
Indexed literature (PubMed)11
Saffati G et al. · Transl Androl Urol · 2024
Rodriguez KM et al. · Expert Opin Pharmacother · 2016
Hohl A et al. · Arch Endocrinol Metab · 2025
Hill S et al. · IDrugs · 2009
Earl JA et al. · Expert Rev Endocrinol Metab · 2019
Franz-Odendaal TA et al. · Plast Surg (Oakv) · 2023
Kim ED et al. · BJU Int · 2016
Thomas J et al. · Cureus · 2023
Wiehle RD et al. · Fertil Steril · 2014
Kaminetsky J et al. · J Sex Med · 2013
Foster J et al. · World J Mens Health · 2026
Keep reading